Mankind Pharma to Acquire 70% Stake in Belgium's Armed Cell Therapeutics for EUR 48Mn
Mankind Pharma will acquire a 70% stake in Belgium's Armed Cell Therapeutics (ACTx) for EUR 48 million through its Dutch subsidiary. The company also approved an additional EUR 45 million investment in its subsidiary, raising the total investment limit to EUR 50 million. ACTx develops next-generation CAR-T therapies for cancer.
This acquisition represents a significant strategic entry into a cutting-edge field of cancer therapy, potentially expanding Mankind Pharma's global product pipeline and market presence in innovative treatments.
The acquisition of a stake in a biotechnology company specializing in next-generation CAR-T therapies for cancer is a strategic move that aligns with the company's long-term vision for innovation and global expansion.
Mankind Pharma Limited announced a significant strategic move through its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., to acquire a majority stake of 70% in Armed Cell Therapeutics B.V. (ACTx), a Belgium-based biotechnology company. This acquisition is part of Mankind Pharma's long-term strategy to build a global innovation-led pharmaceutical business.
The total investment for this acquisition will be EUR 48 million, to be made in installments. Concurrently, the company has approved an additional investment of up to EUR 45 million in Mankind Netherlands, increasing the aggregate investment limit to EUR 50 million, which includes the previously approved EUR 5 million. This expansion will fund the acquisition of ACTx.
ACTx specializes in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer. The company's pipeline includes lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. ACTx's research and development activities are conducted by experienced teams located in the US and EU. The Board of Directors of Mankind Pharma Limited approved these decisions during their meeting held on October 15, 2026, which commenced at 06:00 p.m. IST and concluded at 07:00 p.m. IST.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.